XM does not provide services to residents of the United States of America.

India's Mamaearth parent loses $415 mln in market value as Q2 loss fans demand worries



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>India's Mamaearth parent loses $415 mln in market value as Q2 loss fans demand worries</title></head><body>

By Kashish Tandon and Indranil Sarkar

Nov 19 (Reuters) -Indian skincare firm Mamaearth's parent Honasa Consumer HONA.NS wiped off nearly 35 billion rupees ($414.7 million) in market valuation in two sessions, after a second-quarter loss fanned demand concerns for the beauty products retailer.

The stock touched a record low of 242.35 rupees on Tuesday, and has fallen by about 30% over the last two days. Its market cap has declined to 86 billion rupees.

The sharp selloff was triggered after Honasa posted its first quarterly loss since listing in Nov. 2023 late on Thursday.

It joined a long list of Indian consumer firms such as Hindustan Unilever HLL.NS and Nestle India NEST.NS to report downbeat results this quarter as urban consumers cut spending in the face of high inflation.

A challenging demand scenario and weaker-than-expected performance has hurt the company, analysts at JM Financial said.

Analysts said that Honasa, which competes with larger rival Nykaa FSNE.NS and private players such as Health & Glow, was hurt by stiff competition in India's beauty and personal care industry, whose market size is likely to hit $28 billion by 2025 from $17.8 billion in 2020, per Avendus data.

The competition has forced the company, also known for its brands such as 'The Derma Co' and 'Aqualogica,' to rethink its business strategy, said Arvind Singhal, chairman of consultancy firm Technopak Advisors.

Honasa, which sells its products primarily through online platforms, had said in its post-earnings call that it is planning to scale up its business by shifting its focus more on offline channels.

Analysts at Citi said the move "needs a refresher", and downgraded the stock by two notches to a "sell" from "buy".

The brokerage also cited consumers' shift to more active ingredient-based products from naturals-based products earlier.

At least five analysts downgraded the stock after its results, while nine slashed their price targets, per data compiled by LSEG.


($1 = 84.4000 Indian rupees)



Reporting by Kashish Tandon and Indranil Sarkar in Bengaluru; Editing by Varun H K

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.